Results 101 to 110 of about 13,707 (310)

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

open access: yesRespiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis   +3 more
doaj  

Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion

open access: yesRespirology, Volume 30, Issue 6, Page 466-479, June 2025.
ABSTRACT Treatment targets in severe asthma have evolved towards a remission‐focused paradigm guided by precision medicine. This novel concept requires a shift from evaluating the efficacy of therapies based on a single outcome at a single time point to an outcome that captures the complexity of asthma remission involving several domains assessed over ...
Dennis Thomas   +26 more
wiley   +1 more source

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

open access: yes, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean   +6 more
core   +1 more source

Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions [PDF]

open access: yes, 2018
Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical manifestations and treatment modalities. The disorders are suspected to result from an abnormal inflammatory response to allergen(s), and individuals may ...
Gupta, Sandeep K., Naramore, Sara
core   +1 more source

Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma

open access: yes
Allergy, EarlyView.
Michael Fricker   +3 more
wiley   +1 more source

Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta‐analysis

open access: yesClinical and Translational Allergy, Volume 15, Issue 5, May 2025.
Abstract Background Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head. This systematic review and network meta‐analysis evaluated their relative efficacy and safety.
Zuotao Zhao   +8 more
wiley   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

open access: yesHeliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi   +2 more
doaj  

Distinct Airway Inflammatory Pathways Associated with Asthma Exacerbations are Modulated by Mepolizumab Therapy in Children [PDF]

open access: yes, 2022
Rationale: Identification of specific airway inflammatory pathways can lead to effective personalized treatment with biologics in asthma and insights to mechanisms of action.
Altman, Matthew   +22 more
core   +1 more source

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

open access: yesERJ Open Research
Background In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China.
Ruchong Chen   +13 more
semanticscholar   +1 more source

Persistent Bacterial Bronchitis: time to venture beyond the Umbrella [PDF]

open access: yes, 2017
Chronic cough in children is common and frequently mismanaged. In the past, cough was diagnosed as asthma and inappropriate asthma therapies prescribed and esca- lated.
Bush, A
core   +1 more source

Home - About - Disclaimer - Privacy